Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Nov 16 - Nov 21
In this blog, Sanjiv Lakhanpal, MD, FACS, Founder, President, and CEO of Center for Vein Restoration (CVR), breaks it down in plain language so you can have a more informed conversation with your primary care doctor or vein specialist about using these powerful medications to support health
Theres also a new medication in development that targets three hormones (GLP-1, GIP, and glucagon), which may be even more effective for weight loss
Soudah and colleagues provide a foundation for future investigations into how treatments for metabolic disease might also influence neurological outcomesan area that could reshape approaches to both diabetes and age-related cognitive disorders.
Tirzepatide added a second hormone target (GIP) to make it a dual agonist, and thats why it outperformed semaglutide in head-to-head trials
